8-K: Fennec Pharma's PEDMARK Study Meets Primary Endpoint in Japan

Fennec Pharmaceuticals announced positive Phase 2 results for PEDMARK in Japan, demonstrating significant hearing protection in pediatric cancer patients treated with cisplatin.

Summary

• Fennec Pharmaceuticals Inc. announced positive results from an investigator-initiated Phase 2 clinical study (STS-J01) of PEDMARK in Japan.
• The study evaluated PEDMARK for reducing cisplatin-induced ototoxicity in pediatric and adolescent/young adult (AYA) patients with non-metastatic solid tumors.
• The primary endpoint was met, showing a significant reduction in hearing loss.
• Among 25 patients in the primary efficacy population, ASHA-defined hearing loss occurred in 24.0% compared to a historical benchmark of 56.4% (p=0.001).
• 84% of patients had Grade 0 hearing loss by Brock criteria, with no Grade 3 or Grade 4 hearing loss observed.
• Objective tumor responses were seen in 23 of 24 evaluable patients (95.8%).
• Pharmacokinetic analyses support the six-hour PEDMARK administration interval.
• The safety profile was consistent with known tolerability, with no serious adverse events attributed to PEDMARK.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, indicating significant progress in a key clinical study for a promising drug.

Positives

• The primary endpoint of the Phase 2 STS-J01 study was met, demonstrating a statistically significant reduction in hearing loss (24.0% vs. 56.4% historical benchmark, p=0.001).
• No Grade 3 or Grade 4 hearing loss was observed by Brock criteria, indicating substantial hearing preservation.
• A high objective tumor response rate of 95.8% (23/24 evaluable patients) was observed, reassuring for the drug's efficacy alongside cisplatin.
• Pharmacokinetic data supports the six-hour administration interval for PEDMARK, providing mechanistic insight.
• The safety profile of PEDMARK was consistent with previous findings and no serious adverse events were attributed to the drug.
• PEDMARK is the first and only FDA-approved therapy for reducing cisplatin-induced ototoxicity in pediatric patients and has a 2A NCCN endorsement for AYA patients.
• Fennec is pursuing registration in Japan and exploring partnering/licensing opportunities.

Negatives

• While not a direct negative, the study enrolled 33 patients, with 27 in the primary cohort and 6 in exploratory cohorts, indicating a relatively small sample size.
• The study is investigator-initiated, which, while valuable, differs from a company-sponsored pivotal trial.

Risks

• The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours, as irreversible ototoxicity may have already occurred.
• Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials; patients with sulfite sensitivity may have reactions.
• Hypernatremia occurred in 12% to 26% of patients, including a Grade 3 case; hypokalemia occurred in 15% to 27% of patients.
• The company is exploring partnering or licensing opportunities, indicating potential reliance on external parties for commercialization.
• Forward-looking statements are subject to risks including regulatory changes, scientific data sufficiency, clinical result replication, unforeseen global instability, patent challenges, market size limitations, and funding requirements.

Future Outlook

Fennec Pharmaceuticals is pursuing registration for PEDMARK in Japan and is actively exploring partnering or licensing opportunities for the drug. The company's commercialization efforts for PEDMARK/PEDMARQSI, potential future commercial and regulatory milestones, and royalty payments from Norgine are subject to various risks and uncertainties.

Management Comments

• "The clinical and pharmacologic findings of STS-J01 are compelling. We observed a significant reduction in hearing loss, with no Grade 3 or Grade 4 hearing loss by Brock criteria, alongside a 95.8% objective response rate in evaluable patients."
• "The prospective pharmacokinetic analyses further provide important mechanistic insight into why the six-hour interval matters, supporting a model in which PEDMARK acts on residual circulating and exchangeable platinum after cisplatin has had time to distribute and initiate its antitumor activity."
• "Together, these findings add an important independent body of evidence supporting the clinical rationale for delayed PEDMARK administration."
• "The results from STS-J01 are encouraging because they demonstrate significant hearing protection and provide reassuring clinical context regarding antitumor activity with delayed PEDMARK administration."
• "We believe that these results provide further support and confidence in PEDMARK for healthcare professionals."

Industry Context

StockSavvy.ai notes that the positive results for PEDMARK in Japan align with the ongoing industry trend of developing targeted therapies and supportive care agents to mitigate the severe side effects of established cancer treatments like cisplatin. The focus on preserving quality of life for pediatric cancer survivors by preventing permanent hearing loss addresses a significant unmet need in oncology.

Stakeholder Impact

• Shareholders: Positive clinical data may enhance the perceived value and future prospects of the company, potentially impacting stock price.
• Patients (Pediatric/AYA with solid tumors): Improved quality of life due to reduced risk of permanent hearing loss, a significant side effect of cisplatin chemotherapy.
• Healthcare Professionals: Provides further clinical evidence supporting the use of PEDMARK in preventing ototoxicity, potentially increasing adoption.
• Regulatory Bodies (Japan): Positive data supports the ongoing review process for PEDMARK's registration.

Next Steps

• Pursuing registration of PEDMARK in Japan.
• Exploring partnering or licensing opportunities for PEDMARK.

Key Dates

Recommendation

The positive clinical trial results are significant and address a critical unmet need, supporting the drug's value. However, the company is still in the process of pursuing registration in Japan and exploring partnerships, indicating that commercialization is not yet fully realized. Therefore, a 'hold' recommendation reflects the positive development while acknowledging the remaining execution risks.

Keywords

PEDMARK, ototoxicity, cisplatin, hearing loss, pediatric oncology, clinical trial, sodium thiosulfate, cancer therapy